1 |
Mills KT, Bundy JD, Kelly TN, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries [J]. Circulation, 2016, 134(6): 441-450.
|
2 |
Oh GC, Cho HJ. Blood pressure and heart failure [J]. Clin Hypertens, 2020, 26: 1-8.
|
3 |
中华医学会心血管病学分会心力衰竭学组, 中国医师协会心力衰竭专业委员会, 中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018 [J].中华心血管病杂志, 2018, 46(10): 760-789.
|
4 |
Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC [J]. Eur J Heart Fail, 2016, 18(8): 891-975.
|
5 |
Stewart S, Ekman I, Ekman T, et al. Population impact of heart failure and the most common forms of cancer: a study of 1 162 309 hospital cases in Sweden (1988 to 2004) [J]. Circ Cardiovasc Qual Outcomes, 2010, 3(6): 573-580.
|
6 |
Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to congestive heart failure [J]. JAMA, 1996, 275: 1557-1562.
|
7 |
Yamasaki N, Kitaoka H, Matsumura Y, et al. Heart failure in the elderly [J]. Intern Med, 2003, 42: 383-388.
|
8 |
Group SR, Wright JTJr., Williamson JD, et al. A randomized trial of intensive versus standard bloodpressure control [J]. N Engl J Med, 2015, 373: 2103-2116.
|
9 |
Kannan A, Janardhanan R, Kannan A, et al. Hypertension as a risk factor for heart failure [J]. Curr Hypertens Rep, 2014, 16(7): 447.
|
10 |
López B, Ravassa S, González A, et al. Myocardial collagen cross-linking is associated with heart failure hospitalization in patients with hypertensive heart failure [J]. J Am Coll Cardiol, 2016, 67: 251-260.
|
11 |
Slivnick J, Lampert BC, Slivnick J, et al. Hypertension and heart failure [J]. Heart Fail Clin, 2019, 15(4): 531-541.
|
12 |
Tagawa H, Rozich JD, Tsutsui H, et al. Basis for increased microtubules in pressure-hypertrophied cardiocytes [J]. Circulation, 1996, 93(6): 1230-1243.
|
13 |
Tam MC, Lee R, Cascino TM, et al. Current perspectives on systemic hypertension in heart failure with preserved ejection fraction [J]. Curr Hypertens Rep, 2017, 19(2): 12.
|
14 |
Messerli FH, Rimoldi SF, Bangalore S. The transition from hypertension to heart failure: contemporary update [J]. JACC Heart Fail, 2017, 5(8): 543-551.
|
15 |
Hwang SJ, Melenovsky V, Borlaug BA. Implications of coronary artery disease in heart failure with preserved ejection fraction [J]. J Am Coll Cardiol, 2014, 63(25 Pt A): 2817-2827.
|
16 |
Klingbeil AU, Schneider M, Martus P, et al. A metaanalysis of the effects of treatment on left ventricular mass in essential hypertension [J]. Am J Med, 2003, 115: 41-46.
|
17 |
Sciarretta S, Palano F, Tocci G, et al. Antihypertensive treatment and development of heart failure in hypertension: a Bayesian network meta-analysis of studies in patients with hypertension and high cardiovascular risk [J]. Arch Intern Med, 2011, 171(5): 384-394.
|
18 |
Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis [J]. Lancet, 2016, 387(10022): 957-967.
|
19 |
Group SR, Wright JTJr, Williamson JD, et al. A randomized trial of intensive versus standard blood-pressure control [J]. N Engl J Med, 2015, 373: 2103-2116.
|
20 |
Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with preserved ejection fraction [J]. N Engl J Med, 2021, Aug 27. Online ahead of print.
|
21 |
Banach M, Aronow WS. Blood pressure J-curve: current concepts [J]. Curr Hypertens Rep, 2012, 14: 556-566.
|
22 |
Robles NR, Fici F, Grassi G, et al. J-shaped curve for cardiovascular mortality: systolic or diastolic blood pressure? [J]. J Nephrol, 2019, 32(3): 347-353.
|
23 |
Banach M, Aronow WS. Blood pressure j-curve: current concepts [J]. Curr Hypertens Rep, 2012, 14(6): 556-566.
|
24 |
Lip S, Tan LE, Jeemon P, et al. Diastolic blood pressure J-curve phenomenon in a tertiary-care hypertension clinic [J]. Hypertension, 2019, 74(4): 767-775.
|
25 |
Hansson L. Antihypertensive treatment: does the J-curve exist? [J]. Cardiovasc Drugs Ther, 2000, 14: 367-372.
|
26 |
Böhm M, Ewen S. Blood pressure risk associations in heart failure: true effects or inverse causality? [J]. JACC Heart Fail, 2017, 5(11): 820-822.
|
27 |
Ather S, Chan W, Chillar A, et al. Association of systolic blood pressure with mortality in patients with heart failure with reduced ejection fraction: a complex relationship [J]. Am Heart J, 2011, 161(3): 567-573.
|
28 |
Gheorghiade M, Abraham WT, Albert NM, et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure [J]. JAMA, 2006, 296: 2217-2226.
|
29 |
Abraham WT, Fonarow GC, Albert NM, et al. Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving treatment in hospitalized patients with heart failure (OPTIMIZE-HF) [J]. J Am Coll Cardiol, 2008, 52: 347-356.
|
30 |
Arundel C, Lam PH, Gill GS, et al. Systolic blood pressure and outcomes in patients with heart failure with reduced ejection fraction [J]. J Am Coll Cardiol, 2019, 73(24): 3054-3063.
|
31 |
Faselis C, Lam PH, Zile MR,et al. Systolic blood pressure and outcomes in older patients with HFpEF and hypertension [J]. Am J Med, 2021, 134(4): e252-e263.
|
32 |
Tsimploulis A, Lam PH, Arundel C, et al. Systolic blood pressure and outcomes in patients with heart failure with preserved ejection fraction [J]. JAMA Cardiol, 2018, 3(4):288-297.
|
33 |
Bohm M, Young R, Jhund PS, et al. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan [LCZ696] in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF [J]. Eur Heart J, 2017, 38(15): 1132-1143.
|
34 |
Tsujimoto T, Kajio H. Tsujimoto T, et al. Low diastolic blood pressure and adverse outcomes in heart failure with preserved ejection fraction [J]. Int J Cardiol, 2018, 263: 69-74.
|
35 |
Raphael CE, Whinnett ZI, Davies JE, et al. Quantifying the paradoxical effect of higher systolic blood pressure on mortality in chronic heart failure [J]. Heart, 2009, 95(1): 56-62.
|
36 |
Lee SE, Lee HY, Cho HJ, et al. Reverse J-Curve relationship between on-treatment blood pressure and mortality in patients with heart failure [J]. JACC Heart Fail, 2017, 5(11): 810-819.
|
37 |
Messerli FH, Rimoldi SF, Bangalore S, et al. The transition from hypertension to heart failure: contemporary update [J]. JACC Heart Fail, 2017, 5(8): 543-551.
|
38 |
Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension [J]. J Hypertens, 2018, 36(10): 1953-2041.
|
39 |
Cautela J, Tartiere JM, Cohen-Solal A, et al. Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients [J]. Eur J Heart Fail, 2020, 22(8): 1357-1365.
|
40 |
Lee MH, Leda M, Buchan T, et al. Prognostic value of blood pressure in ambulatory heart failure: a meta-analysis and systematic review. Ambulatory blood pressure predicts heart failure prognosis [J]. Heart Fail Rev, 2021, Mar 8. Online ahead of print.
|